



**HIV, Hepatitis and Overdose among Drug Users:
The Health Department Role in an Effective Response**

**444 North Capitol Street NW – Room 333
Washington, DC**

April 22-23, 2014

Meeting Goal: To provide a venue for health department HIV and viral hepatitis staff to examine their efforts to reduce HIV and HCV transmission and overdose among persons who inject drugs, and to develop plans to expand their efforts through the framework of drug user health.

Tuesday, April 22

2:00 – 2:30 Welcome and Introductions

*Julie Scofield, Executive Director
National Alliance of State and Territorial AIDS Directors*

**2:30 – 3:30 Defining the Problem and Prioritizing a Response:
HIV, HCV, Drug Use and Overdose in the U.S.**

*Daniel Raymond, Policy Director
Harm Reduction Coalition*

*Alessandra Ross, Injection Drug Use Specialist
California Department of Public Health*

3:30 – 5:00 Modernizing Our Approach to Drug User Health

Brief remarks on innovative approaches to reimagine and modernize the public health approach to drug user health followed by a facilitated discussion of opportunities in participating states. At the end of the session, participants will be asked to identify key collaborators, actions that health departments can take, and recommendations for NASTAD.

*Rachel McLean, Viral Hepatitis Prevention Coordinator
California Department of Health*

[Dave Kern, Manager, Infectious Disease Prevention
Washington State Department of Health](#)

[Alisa Solberg, Director
Point Defiance Aids Projects, Tacoma, Washington](#)

*Moderator: Natalie Cramer, Director, Prevention
National Alliance of State and Territorial AIDS Directors*

5:00 – 5:30 Preview of Day Two

*Chris Taylor, Associate Director, Viral Hepatitis
National Alliance of State and Territorial AIDS Directors*

5:30 Adjourn

Wednesday, April 23

8:30 – 9:00 Breakfast (Provided)

9:00 – 10:30 2014 Federal Priorities to Address HIV/HCV/Overdose

Representatives from key federal agencies will discuss programmatic and policy priorities related to HIV, HCV and overdose prevention, followed by a facilitated discussion with meeting participants. At the end of the session, participants will be asked to identify key collaborators, actions that health departments can take, and recommendations for NASTAD and federal agencies.

*Christine Kourtides, Senior Policy Advisor
Office of National Drug Control Policy*

[Amy Lansky, Deputy Director
Division of HIV/AIDS Prevention, CDC](#)

[Jon Zibbell, Health Scientist/Medical Anthropologist
Division of Viral Hepatitis, CDC](#)

[Melinda Campopiano, Medical Officer
Substance Abuse and Mental Health Services Administration](#)

*Moderator, Murray Penner, Deputy Executive Director
National Alliance of State and Territorial AIDS Directors*

10:30 – 12:00 Infectious Diseases and Injection Drug Use

A facilitated discussion of what is occurring in participating states related to HIV and HCV prevention among people who inject drugs. Participants are encouraged to discuss what is occurring in their jurisdiction, what programs they would like to create/scale up and challenges they are experiencing. Health departments with extensive experience addressing these needs will participate in the discussion and share their expertise. At the end of the session, participants will be asked to identify key collaborators, actions that health departments can take, and recommendations for NASTAD. The following topics will help guide the discussion:

- Syringe Services Programs
- Surveillance and Data
- Policies and Legislation
- Funding and Grantees
- Young People who Inject Drugs
- Increased awareness/action related to overdose
- New HCV Treatments

*Facilitator: Stephen Jones, Consultant
T. Stephen Jones Consulting*

12:00 – 1:00 Lunch (Provided)**1:00 – 2:30 Overdose Prevention: The State Response**

A facilitated discussion of what is occurring in participating states related to overdose prevention among people who inject drugs. Participants are encouraged to discuss what is occurring in their jurisdiction, what programs they would like to create/scale up and challenges they are experiencing. Health departments with extensive experience addressing these needs will participate in the discussion and share their expertise. At the end of the session, participants will be asked to identify key collaborators, actions that health departments can take, and recommendations for NASTAD. The following topics will help guide the discussion:

- Infectious Disease Role
- Cross Program Collaboration
- Data and Trends
- Funding and Grantees
- Policies and Legislation
- Increased awareness/action related to overdose

*Facilitator: Sharon Stancliff, Medical Director
Harm Reduction Coalition*

2:30 – 3:30

Action Agenda Development

Meeting participants will have time to identify projects to focus on related to drug user health over the next twelve months and what technical assistance they will need to be successful.

*Natalie Cramer, Director, Prevention
National Alliance of State and Territorial AIDS Directors*

*Chris Taylor, Associate Director, Viral Hepatitis
National Alliance of State and Territorial AIDS Directors*

3:30 – 4:00

Sharing of Action Agenda – Technical Assistance Needs

*Natalie Cramer, Director, Prevention
National Alliance of State and Territorial AIDS Directors*

*Chris Taylor, Associate Director, Viral Hepatitis
National Alliance of State and Territorial AIDS Directors*

4:00 – 4:30

Next Steps

*Murray Penner, Deputy Executive Director
National Alliance of State and Territorial AIDS Directors*

4:30

Adjourn